Results 11 to 20 of about 9,958,775 (335)

Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer [PDF]

open access: yesESMO Open, 2020
Background Antibody-dependent cell-mediated cytotoxicity (ADCC) may mediate antitumour activity of IgG1-isotype monoclonal antibody (mAb), suggesting as potential treatment combination of IgG1-mAbs, anti-epidermal growth factor receptor cetuximab and ...
M. Fasano   +17 more
semanticscholar   +2 more sources

Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors [PDF]

open access: yesTheranostics, 2018
Monoclonal antibodies (mAbs) have significantly improved the treatment of certain cancers. However, in general mAbs alone have limited therapeutic activity. One of their main mechanisms of action is to induce antibody-dependent cell-mediated cytotoxicity
D. Sánchez-Martínez   +17 more
semanticscholar   +2 more sources

Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies [PDF]

open access: yeseLife, 2021
A prerequisite for the design of an HIV vaccine that elicits protective antibodies is understanding the developmental pathways that result in desirable antibody features. The development of antibodies that mediate antibody-dependent cellular cytotoxicity
Laura E Doepker   +15 more
doaj   +2 more sources

An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity

open access: yesTransfusion Medicine and Hemotherapy, 2017
Background: Engineering of the antibody's fragment crystallizable (Fc) by modifying the amino acid sequence (Fc protein engineering) or the glycosylation pattern (Fc glyco-engineering) allows enhancing effector functions of tumor targeting antibodies ...
Tim Wirt   +12 more
semanticscholar   +2 more sources

HUMAN MONONUCLEAR CELL ANTIBODY DEPENDENT CELL-MEDIATED CYTOTOXICITY TOWARD RBC OF VARIOUS RH GENOTYPE.

open access: yes, 1980
HUMAN MONONUCLEAR CELL ANTIBODY DEPENDENT CELL-MEDIATED CYTOTOXICITY TOWARD RBC OF VARIOUS RH ...
ARTHUR DEAN JR. JABS (7976831)
core   +4 more sources

Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer

open access: yesClinical Cancer Research, 2020
Purpose: Antibody-dependent cell-mediated cytotoxicity (ADCC) is one mechanism of action of the monoclonal antibody (mAb) therapies trastuzumab and pertuzumab.
D. Collins   +22 more
semanticscholar   +1 more source

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma

open access: yesFrontiers in Immunology, 2023
BackgroundDespite recent advances in the treatment of aggressive lymphomas, a significant fraction of patients still succumbs to their disease. Thus, novel therapies are urgently needed. As the anti-CD20 antibody rituximab and the CD19-targeting antibody
Maria Patra-Kneuer   +22 more
doaj   +1 more source

Characterization of IgG1 Fc Deamidation at Asparagine 325 and Its Impact on Antibody-dependent Cell-mediated Cytotoxicity and FcγRIIIa Binding

open access: yesScientific Reports, 2020
Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism of action for many therapeutic antibodies. A therapeutic immunoglobulin (Ig) G1 monoclonal antibody lost more than half of its ADCC activity after heat stress at 40 °C for 4 ...
X. Lu   +7 more
semanticscholar   +1 more source

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

open access: yesHaematologica, 2011
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer   +7 more
doaj   +1 more source

Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies

open access: yesbioRxiv, 2020
A prerequisite for the design of an HIV vaccine that elicits protective antibodies is understanding the developmental pathways that result in desirable antibody features. The development of antibodies that mediate antibody-dependent cellular cytotoxicity
Laura E. Doepker   +15 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy